Wasatch Advisors’s Castle Biosciences CSTL Stock Holding History

Wasatch Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.9M	Sell	279,343 -6	-0%	-$181	0.07%	131
2026 Q2	$6.66M	Sell	279,349 -175,687	-39%	-$3.91M	0.04%	163
2026 Q1	$11.2M	Sell	455,036 -82,205	-15%	-$2.69M	0.07%	124
2025 Q4	$20.9M	Sell	537,241 -131,879	-20%	-$4.25M	0.12%	124
2025 Q3	$15.2M	Sell	669,120 -380,653	-36%	-$7.73M	0.08%	138
2025 Q2	$21.4M	Buy	1,049,773 +51,318	+5%	+$950K	0.11%	129
2025 Q1	$20M	Sell	998,455 -797,633	-44%	-$19.7M	0.11%	128
2024 Q4	$47.9M	Sell	1,796,088 -30,004	-2%	-$914K	0.24%	99
2024 Q3	$52.1M	Sell	1,826,092 -501,844	-22%	-$12.8M	0.26%	94
2024 Q2	$50.7M	Sell	2,327,936 -223,152	-9%	-$4.97M	0.27%	86
2024 Q1	$56.5M	Sell	2,551,088 -39,863	-2%	-$867K	0.3%	84
2023 Q4	$55.9M	Sell	2,590,951 -189,793	-7%	-$3.34M	0.31%	79
2023 Q3	$47M	Sell	2,780,744 -306,257	-10%	-$5.36M	0.3%	80
2023 Q2	$42.4M	Buy	3,087,001 +107,088	+4%	+$2.17M	0.26%	85
2023 Q1	$67.7M	Sell	2,979,913 -242,649	-8%	-$5.93M	0.42%	67
2022 Q4	$75.9M	Sell	3,222,562 -122,185	-4%	-$2.83M	0.51%	59
2022 Q3	$87.2M	Sell	3,344,747 -360,771	-10%	-$10.1M	0.61%	52
2022 Q2	$81.3M	Buy	3,705,518 +261,671	+8%	+$6.08M	0.51%	66
2022 Q1	$154M	Buy	3,443,847 +327,359	+11%	+$13.5M	0.76%	46
2021 Q4	$134M	Buy	3,116,488 +622,786	+25%	+$32.5M	0.55%	63
2021 Q3	$166M	Sell	2,493,702 -11,196	-0.4%	-$788K	0.67%	51
2021 Q2	$184M	Buy	2,504,898 +151,419	+6%	+$10M	0.75%	45
2021 Q1	$161M	Buy	2,353,479 +288,648	+14%	+$21.7M	0.72%	50
2020 Q4	$139M	Buy	2,064,831 +686,774	+50%	+$37.2M	0.68%	53
2020 Q3	$70.9M	Buy	1,378,057 +286,275	+26%	+$12.7M	0.45%	73
2020 Q2	$41.1M	Buy	1,091,782 +441,637	+68%	+$15.1M	0.3%	94
2020 Q1	$19.4M	Buy	650,145 +273,778	+73%	+$8.26M	0.2%	98
2019 Q4	$12.9M	Buy	376,367 +100,856	+37%	+$2.47M	0.11%	131
2019 Q3	$4.98M	Buy	+275,511	New	+$6.11M	0.05%	184

Other funds holding CSTL

FBT

First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Wasatch Advisors's CSTL Position: Q3 2026 in Review

Wasatch Advisors reduced its Castle Biosciences (CSTL) stake by 0% in Q3 2026, selling an estimated $181 and leaving 279,343 shares worth $9.9M. The position accounts for 0.07% of the portfolio, ranked #131.

Wasatch Advisors first reported a position in CSTL in Q3 2019 and has held it in 29 quarters since. The position peaked at $184M in Q2 2021. 13 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Wasatch Advisors held 279,343 shares of Castle Biosciences worth $9.9M as of Q3 2026.
Wasatch Advisors sold 6 Castle Biosciences shares in Q3 2026, an estimated $181.
Castle Biosciences made up 0.07% of Wasatch Advisors's portfolio in Q3 2026, its #131 holding.
Wasatch Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 29 quarters since.
Wasatch Advisors's Castle Biosciences position peaked at $184M in Q2 2021.
13 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Wasatch Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.